Prescribing information

 

_

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Image with the words The first and only fully human targeted IL-17A inhibitor

Image with the words Recommended by BAD as the first-line biologic for patients with PsO, with or without PsA

Image with the words Real-world evidence from BADBIR, one of the largest national psoriasis registries in the world

 

What difference can Cosentyx make for your patients?

With over 400,000 patients treated with Cosentyx* (across all indications) since launch4, Cosentyx offers fast and long-lasting improvements so your patients can...

 

 
Image for Cosentyx provides reassurance of a consistent safety profile in clinical trials up to 5 years across PsO, PsA and AS
Image for Cosentyx is at the heart of the You First programme--a personal and consistent nurse-led support which is provided to Cosentyx patients at home
 

 

*Worldwide, across all licensed indications.4

BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; IL, interleukin; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; PsO, plaque psoriasis; QoL, quality of life.

References

  1. Cosentyx Summary of Product Characteristics.
  2. Smith CH et al. Br J Dermatol 2020;183(4):628–637.
  3. Yiu et al. Br J Dermatol 2020; 2020;183(2):294–302.
  4. Rheumatology DOF UK 311.
  5. Thaci D et al. J Am Acad Dermatol 2015;7(3):400–409.
  6. Langley RG et al. N Engl J Med 2014;371(4):326–338.
  7. Blauvelt A et al. J Am Acad Dermatol 2017;76(1):60–69.
  8. Bissonnette R et al. J Eur Acad Dermatol Venereol 2018;32:1507–1514.
  9. Rheumatology DOF UK 215.     
  10. Mease P et al. Ann Rheum Dis 2018;77(6);890–897.
  11. Mease P et al. ACR Open Rheum 2020;2(1):18–25.
  12. Baraliakos X et al. RMD Open 2019;5(2):e001005.
  13. Feldman SR et al. J Derm Treat 2020; doi:10.1080/09546634.2019.1708854.
  14. Deodhar A et al. Arthritis Res Ther 2019;21:111.

 

Rate this content: 
No votes yet
UK | January 2021 | 100185
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]